ROIV logo

Roivant Sciences (ROIV) EBITDA

annual EBITDA:

-$1.10B-$296.72M(-36.96%)
March 1, 2025

Summary

  • As of today (July 3, 2025), ROIV annual EBITDA is -$1.10 billion, with the most recent change of -$296.72 million (-36.96%) on March 1, 2025.
  • During the last 3 years, ROIV annual EBITDA has fallen by -$188.84 million (-20.73%).
  • ROIV annual EBITDA is now -39.16% below its all-time high of -$790.16 million, reached on March 31, 2023.

Performance

1-year change

-36.96%

3-year change

-20.73%

5-year change

-22.76%

15-year change

-22.76%

ROIV EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

0.4%
ROIV annual EBITDA is higher than 0.4% of companies in Healthcare sector

Range

All-time high

-$790.16M

3-year low

-$1.10B
ROIV annual EBITDA is currently at its 3-year low

Earnings dates

Last annual earnings report date

Mar 1, 2025
ROIV previous annual earnings announcement was published on Mar 1, 2025

Next annual earnings report date

N/A
ROIV next annual earnings announcement has not yet been scheduled

OtherROIVincome statement metrics

Annual revenue

$29.05M
ROIV annual revenue is $29.05 million

annual net income

-$171.98M
ROIV annual net profit is -$171.98 million

annual EBIT

-$1.11B
ROIV annual earnings before interest & taxes is -$1.11 billion

Annual EPS

-$0.24
ROIV annual earnings per share is -$0.24

quarterly EBITDA:

-$283.54M-$12.08M(-4.45%)
March 1, 2025

Summary

  • As of today (July 3, 2025), ROIV quarterly EBITDA is -$283.54 million, with the most recent change of -$12.08 million (-4.45%) on March 1, 2025.
  • Over the past year, ROIV quarterly EBITDA has dropped by -$81.93 million (-40.64%).
  • ROIV quarterly EBITDA is now -227.05% below its all-time high of $223.16 million, reached on March 31, 2023.

Performance

3-month change

-4.45%

1-year change

-40.64%

3-year change

+1.65%

5-year change

-147.73%

ROIV quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

0.68%
ROIV quarterly EBITDA is higher than 0.68% of companies in Healthcare sector

Range

All-time high

$223.16M
ROIV quarterly EBITDA is currently -227.05% below its historical high of $223.16 million

3-year low

-$368.48M

Earnings dates

Last quarterly earnings report date

Mar 1, 2025
ROIV previous earnings announcement was published on Mar 1, 2025

Next quarterly earnings report date

Aug 8, 2025
ROIV next earnings announcement is scheduled for Aug 8, 2025

OtherROIVincome statement metrics

Quarterly revenue

$7.57M
ROIV quarterly revenue is $7.57 million

quarterly net income

-$206.47M
ROIV quarterly net profit is -$206.47 million

quarterly EBIT

-$284.96M
ROIV quarterly earnings before interest & taxes is -$284.96 million

Quarterly EPS

-$0.29
ROIV quarterly earnings per share is -$0.29

TTM EBITDA:

-$803.44M-$81.93M(-11.36%)
March 1, 2025

Summary

  • As of today (July 3, 2025), ROIV TTM EBITDA is -$803.44 million, with the most recent change of -$81.93 million (-11.36%) on March 1, 2025.
  • Over the past year, ROIV TTM EBITDA has increased by +$119.43 million (+12.94%).
  • ROIV TTM EBITDA is now -601.99% below its all-time high of -$114.45 million, reached on June 1, 2020.

Performance

3-month change

-11.36%

1-year change

+12.94%

3-year change

+12.06%

5-year change

-601.99%

ROIV TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

0.6%
ROIV TTM EBITDA is higher than 0.6% of companies in Healthcare sector

Range

All-time high

-$114.45M

3-year low

-$1.30B

Earnings dates

Last quarterly earnings report date

Mar 1, 2025
ROIV previous earnings announcement was published on Mar 1, 2025

Next quarterly earnings report date

Aug 8, 2025
ROIV next earnings announcement is scheduled for Aug 8, 2025

OtherROIVincome statement metrics

TTM revenue

$76.19M
ROIV TTM revenue is $76.19 million

TTM net income

-$171.98M
ROIV TTM net profit is -$171.98 million

TTM EBIT

-$817.51M
ROIV TTM earnings before interest & taxes is -$817.51 million

TTM EPS

-$0.25
ROIV TTM earnings per share is -$0.25

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

annual EBITDA

-$1.10B
ROIV annual EBITDA is -$1.10 billion

annual net income

-$171.98M
ROIV annual net profit is -$171.98 million

annual interest expense

-
ROIV annual interest expense value is unknown

annual income tax

$48.17M
ROIV annual income tax is $48.17 million

annual D&A

$14.07M
ROIV annual depreciation & amortization is $14.07 million

ROIV EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-37.0%-40.6%+12.9%
3 y3 years-20.7%+1.6%+12.1%
5 y5 years-22.8%-147.7%-602.0%

ROIV EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-39.2%at low-227.1%+23.1%-61.3%+38.3%
5 y5-year-39.2%at low-227.1%+23.1%-602.0%+38.3%
alltimeall time-39.2%at low-227.1%+23.1%-602.0%+38.3%

ROIV EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-$1.10B(+37.0%)
-$283.54M(+4.5%)
-$803.44M(+11.4%)
Dec 2024
-
-$271.46M(-19.4%)
-$721.51M(+8.4%)
Sep 2024
-
-$336.87M(-481.0%)
-$665.62M(+27.2%)
Jun 2024
-
$88.43M(-143.9%)
-$523.11M(-43.3%)
Mar 2024
-$802.89M(+1.6%)
-$201.61M(-6.5%)
-$922.88M(+85.3%)
Dec 2023
-
-$215.57M(+10.9%)
-$498.10M(-23.5%)
Sep 2023
-
-$194.35M(-37.6%)
-$651.01M(-14.0%)
Jun 2023
-
-$311.34M(-239.5%)
-$757.00M(-4.2%)
Mar 2023
-$790.16M
$223.16M(-160.6%)
-$790.16M(-39.3%)
Dec 2022
-
-$368.48M(+22.7%)
-$1.30B(+5.3%)
DateAnnualQuarterlyTTM
Sep 2022
-
-$300.35M(-12.8%)
-$1.24B(+6.6%)
Jun 2022
-
-$344.50M(+19.5%)
-$1.16B(+26.9%)
Mar 2022
-$910.77M(+1.7%)
-$288.30M(-4.9%)
-$913.63M(-7.8%)
Dec 2021
-
-$303.18M(+35.5%)
-$991.01M(+4.7%)
Sep 2021
-
-$223.69M(+127.2%)
-$946.90M(+7.6%)
Jun 2021
-
-$98.47M(-73.1%)
-$879.76M(-1.8%)
Mar 2021
-$895.74M
-$365.67M(+41.1%)
-$895.74M(+69.0%)
Dec 2020
-
-$259.07M(+65.5%)
-$530.06M(+95.6%)
Sep 2020
-
-$156.54M(+36.8%)
-$270.99M(+136.8%)
Jun 2020
-
-$114.45M
-$114.45M

FAQ

  • What is Roivant Sciences annual EBITDA?
  • What is the all time high annual EBITDA for Roivant Sciences?
  • What is Roivant Sciences annual EBITDA year-on-year change?
  • What is Roivant Sciences quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Roivant Sciences?
  • What is Roivant Sciences quarterly EBITDA year-on-year change?
  • What is Roivant Sciences TTM EBITDA?
  • What is the all time high TTM EBITDA for Roivant Sciences?
  • What is Roivant Sciences TTM EBITDA year-on-year change?

What is Roivant Sciences annual EBITDA?

The current annual EBITDA of ROIV is -$1.10B

What is the all time high annual EBITDA for Roivant Sciences?

Roivant Sciences all-time high annual EBITDA is -$790.16M

What is Roivant Sciences annual EBITDA year-on-year change?

Over the past year, ROIV annual EBITDA has changed by -$296.72M (-36.96%)

What is Roivant Sciences quarterly EBITDA?

The current quarterly EBITDA of ROIV is -$283.54M

What is the all time high quarterly EBITDA for Roivant Sciences?

Roivant Sciences all-time high quarterly EBITDA is $223.16M

What is Roivant Sciences quarterly EBITDA year-on-year change?

Over the past year, ROIV quarterly EBITDA has changed by -$81.93M (-40.64%)

What is Roivant Sciences TTM EBITDA?

The current TTM EBITDA of ROIV is -$803.44M

What is the all time high TTM EBITDA for Roivant Sciences?

Roivant Sciences all-time high TTM EBITDA is -$114.45M

What is Roivant Sciences TTM EBITDA year-on-year change?

Over the past year, ROIV TTM EBITDA has changed by +$119.43M (+12.94%)
On this page